Physician profile
Joyce John
NPI 1275998833
$3,028.79
in general payments reported to CMS, 2019-2025
19 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $621 · 2023: $1,334 · 2024: $742 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $848.73 | 2021-2023 | Nuplazid |
| Neurocrine Biosciences, INC. | $518.16 | 2022-2023 | Ingrezza |
| Novo Nordisk INC | $253.14 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $197.75 | 2023-2025 | |
| Lundbeck LLC | $187.76 | 2023-2024 | Vyepti, Rexulti |
| Medtronic, INC. | $135.21 | 2023 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $133.71 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $126.00 | 2024 | |
| Sk Life Science, INC. | $114.48 | 2022 | |
| Exact Sciences Corporation | $93.03 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $78.93 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $58.69 | 2025 | Rexulti |
| Lilly USA, LLC | $56.59 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $55.87 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $55.56 | 2023-2024 | Arexvy, Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $42.46 | 2023-2024 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $35.70 | 2025 | Airsupra |
| Astellas Pharma US INC | $22.78 | 2024 | Veozah |
| Lexicon Pharmaceuticals, INC. | $14.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.